Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-07
1999-09-14
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 94, 514 18, 514212, 5142278, 514237, 514340, 514342, 514343, 514469, 514424, 514365, 514423, A61K 3140, A61K 3800, A61K 3154, A61K 3134
Patent
active
059523050
ABSTRACT:
The invention involves a method for treating a human survivor of a heart attack and provides further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angiotensin converting enzyme inhibitor. The inhibitor may be used on its own, or in conjunction with other therapeutic compounds such as data blockers and thrombolytic agents. The preferred inhibitor is captopril.
REFERENCES:
patent: 3932624 (1976-01-01), Fulton
patent: 4105776 (1978-08-01), Ondetti et al.
patent: 4302386 (1981-11-01), Stevens
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4410520 (1983-10-01), Watthey
patent: 4508729 (1985-04-01), Vincent et al.
patent: 4512924 (1985-04-01), Attwood et al.
patent: 4587258 (1986-05-01), Gold et al.
patent: 4772684 (1988-09-01), Brunck et al.
patent: 4780401 (1988-10-01), Heusser et al.
patent: 4816463 (1989-03-01), Blankley et al.
patent: 4845079 (1989-07-01), Luly et al.
patent: 4885292 (1989-12-01), Ryono et al.
patent: 4894437 (1990-01-01), TenBrick
patent: 4980283 (1990-12-01), Huang et al.
patent: 5034512 (1991-07-01), Hudspeth et al.
patent: 5036053 (1991-07-01), Himmelsbach et al.
patent: 5036054 (1991-07-01), Kaltenbronn et al.
patent: 5055466 (1991-10-01), Weller, III et al.
patent: 5063207 (1991-11-01), Doherty et al.
patent: 5063208 (1991-11-01), Rosenberg et al.
patent: 5064825 (1991-11-01), Chakravarty et al.
patent: 5064965 (1991-11-01), Ocain et al.
patent: 5066643 (1991-11-01), Abeles et al.
patent: 5071837 (1991-12-01), Doherty et al.
patent: 5073566 (1991-12-01), Lifer et al.
patent: 5075451 (1991-12-01), Ocain et al.
patent: 5081127 (1992-01-01), Carini et al.
patent: 5085992 (1992-02-01), Chen et al.
patent: 5087634 (1992-02-01), Reitz et al.
patent: 5095006 (1992-03-01), Bender et al.
patent: 5095119 (1992-03-01), Ocain et al.
patent: 5098471 (1992-03-01), Hanson et al.
patent: 5098924 (1992-03-01), Poss
patent: 5104869 (1992-04-01), Albright et al.
patent: 5106835 (1992-04-01), Albright et al.
patent: 5114937 (1992-05-01), Hamby et al.
patent: 5116835 (1992-05-01), Ruger et al.
patent: 5264447 (1993-11-01), Ohtawa
patent: 5266583 (1993-11-01), Ohtawa
Michel J, Lattion A, Salzmann J, de Lourdes Cerol M, Philippe M, Camilleri J, Corvol P. Hormonal and cardiac effects of converting enzyme inhibition in rat myocardial infarction. Circ Res. 62(4):641-650, 1988.
Litwin S, Litwin C, Raya T, Warner A, Goldman S. Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition. Circulation. 83(3):1028-37, 1991.
Sharpe N, Smith H, Murphy J, Greaves S, Hart H, Gamble G. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibition. Lancet. 337:872-76, 1991.
Pinto Y, Wijngaarden J, van Gilst W, de Graeff P, Wesseling H. The effects of short-and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Res Cardiol. 86(Suppl 1):165-72, 1991.
van Krimpen C, Shoemaker R, Cleutjens J, Smits J, Struyker-Boudier H, Boman F, Daemen M. Angiotensin I converting enzyme inhibitors and cardiac remodeling. Basic Res Cardiol. 86(Suppl 1):149-55, 1991.
Clozel J. Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats. Br J Clin Pharmac. 27:167S-174S, 1989.
Dzau V, Creager M. Progress in Angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. Cardiology Clinics. 7(1);1 19- 130, 1989.
Howes L, Hodsman G, Rowe P, Johnston C. Comparative effects of angiotensin converting enzyme inhibition (perindopril) or diuretic therapy on cardiac hypertrophy and sympathetic activity following myocardial infarction in rats. Cardiovasc Drugs Ther. 5:147-152, 1991.
Tio R, de Langen C, de Graeff P, van Gilst W, Bel K, Wolters K, Mook P, Wijngaarden J, Wesseling H. The effects of oral pretreatment with zofenopril, an angiotensin- converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig. Cardiovasc Drugs Ther. 4:695-704, 1990.
Ribout C, Rochette L. Converting enzyme inhibitors (captopril, enalapril, perindopril) prevent early-post infarction ventricular fibrillation in the anaesthetized rat. Cardiovasc Drugs Ther. 1:51-55, 1987.
Michel J. Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure. European Heart Journal. 1 1 (Suppl D):1 7-26, 1990.
Tobe T, de Langen C, Weersink E, Wijngaarden J, Bel K, de Graeff P, van Gilst W, Wesseling H. The Angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs. Journal of Cardiovascular Pharmacology. 19:732-740, 1992.
Lindpaintner K, Niedermaier N, Drexier H, Ganten D. Left ventricular remodeling after myocardial infarction: does the cardiac renin-angiotensin system play a role? journal of Cardiovascular Pharmacology. 20(Suppl 1):S41-S47, 1992.
Nelissen-Vrancken H, Struijker-Boudier H, Smits J. Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats. Journal of Cardiovascular Pharmacology. 19:163-168, 1992.
Sharpe N. Angiotensin-converting enzyme inhibitors in heart failure: a role after myocardial infarction. Journal of Cardiovascular Pharmacology. 18(Suppl 2):S99-S104/ 1991.
Hall A, Winter C, Bogle S, Mackintosh A, Murray G, Ball S. The acute infarction ramipril efficacy (AIRE) study: rationale, design, organization, and outcome definitions. journal of Cardiovascular Pharmacology. 18(Suppi 2):S1 05-S1 09, 1991.
McMurray J, MacLenachan J, Dargie H. Unique cardioprotective potential of angiotensin converting enzyme inhibitors: a hypothesis still to be tested on humans. Journal of Hypertension. 9:393-397, 1991.
Timmermans P, Wong P, Chits A, Herblin W. Nonpeptide angiotensin 11 receptor antagonists. TIPS. 12:55-62, 1991.
Sharpe N. Early preventive treatment of left ventricular dysfunction following myocardial infarction: optimal timing and patient selection. Am J Cardiol. 68:64D-69D, 1991.
Moye L, Pfeffer M, Braunwaid E for the SAVE Investigators. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol. 68:70D-79D, 1991.
ISIS-4 Collaborative Group. Fourth international study of infarct survival: protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. Am J Cardiol. 68:87D-1 OOD, 1991.
Ambrosioni E, Borghi C, Magnani B for the SMILE Pilot Study Working Party. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. Am J Cardiol. 68:1 01 D-1 1 OD, 1991.
van Gilst W, Kingma J. for the CATS Investigators Group. Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in actue myocardial infarction: rationale and design of captopril and thrombolysis study. Am J Cardiol. 68:1 1 1 D-1 15D, 1991.
Pfeffer M, Braunwaid E. Ventricular enlargement following infarction is a modifiable process. Am J Cardiol. 68:127D-1 31 D, 1991.
Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left Ventricular diastolic pressure-volume relations in rats with healed myocardial infarction: effects on systolic function. Circ Res. 1981; 49:618-626.
Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc. Nat'l Acad Sci. 1982; 79:3310-3314.
Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res. 1984; 55:669-675.
Pfeffer MA, Pfeffer JM, Steinberg C,
Braunwald Eugene
Pfeffer Janice M.
Pfeffer Marc A.
Brigham and Women's Hospital, Inc.
Criares Theodore J.
LandOfFree
Methods for reducing risk of repeat myocardial infarction and in does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing risk of repeat myocardial infarction and in, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing risk of repeat myocardial infarction and in will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1509774